Navegar por autor "Constenla Figueiras, Manuel"

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

2019- Barnadas, A.; Munoz, M.; Margeli, M.; Chacon, J. I.; Cassinello, J.; [et al.]

Control of SOCS1 and SOCS3 methylation, and relationship with MGMT as effectiveness factor of treatment in glioblastoma.

2013- Constenla Figueiras, Manuel; López López, Rafael; Herranz Carnero, Michel; Ruibal Morell, Alvaro; Fiaño Valverde, Maria Concepción; [et al.]

Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study

2020- Suh Oh, Hae Jin; Florez Menendez, Maria Angeles; Sacristán Santos, Víctor; Fernández Ribeiro, María Francisca; Vilanova Trillo, Lucía; [et al.]

Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy

2014- Constenla Figueiras, Manuel; López López, Rafael; Bello López, José Luis

Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention

2017-09- Cueva Bañuelos, Juan Fernando; Antolín Novoa, Silvia; Calvo Martínez, Lourdes; Fernández, I; Ramos, M; [et al.]

Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer

2013- Constenla Figueiras, Manuel

Pazopanib in metastatic renal carcinoma (mRC): Experience of 31 centers in Spain in first, second, third, or subsequent lines in daily clinical practice

2013- Constenla Figueiras, Manuel; Vázquez Estévez, Sergio

Prevalence of cancer-related pain in different tumor entities, atlas study in Spanish oncology units

2015- Constenla Figueiras, Manuel; García Mata, Jesús; Vázquez Estévez, Sergio

Prevalence of cancer-related pain in different tumor entities: ATLAS Study in Spanish oncology units

2015- Constenla Figueiras, Manuel; García Mata, Jesús; Vázquez Estévez, Sergio

Prospective study into the necessity of hemogram on day 8 in oral vinorelbine and cisplatin regimen

2012- Constenla Figueiras, Manuel

Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study

2011- Constenla Figueiras, Manuel

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

2012- Reboredo Lopez, Margarita; Constenla Figueiras, Manuel

Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): A randomized, noninferiority phase II trialwith a pharmacogenetic analysis

2015- Constenla Figueiras, Manuel

The BOMET-QOL questionnaire in patients with breast cancer and bone metastasis: The prospective MABOMET study from the Spanish breast cancer research group (GEICAM)

2013- Constenla Figueiras, Manuel

Third line chemotherapy in metastatic colorectal cancer: A single institution experience

2013- Constenla Figueiras, Manuel; Gallardo Martín , Maria Elena; García Arroyo, Francisco Ramón; Carbonel Luyo, Wilver Federico; Cousillas Castiñeiras, Antía; [et al.]

Tolerability of raltitrexed when it is used in monotherapy and in combination with oxaliplatin (TOMOX) as advanced colorectal cancer treatment in normal clinical practice

2013- Constenla Figueiras, Manuel

Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts

2019- Camps Herrero, Carlos; Anton Torres, Antonio; Cruz-Hernandez, Juan Jesus; Carrato, Alfredo; Constenla Figueiras, Manuel; [et al.]

Repositorio digital RUNA

Navegar por autor "Constenla Figueiras, Manuel"

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study ﻿

Control of SOCS1 and SOCS3 methylation, and relationship with MGMT as effectiveness factor of treatment in glioblastoma. ﻿

Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study ﻿

Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy ﻿

Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention ﻿

Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer ﻿

Pazopanib in metastatic renal carcinoma (mRC): Experience of 31 centers in Spain in first, second, third, or subsequent lines in daily clinical practice ﻿

Prevalence of cancer-related pain in different tumor entities, atlas study in Spanish oncology units ﻿

Prevalence of cancer-related pain in different tumor entities: ATLAS Study in Spanish oncology units ﻿

Prospective study into the necessity of hemogram on day 8 in oral vinorelbine and cisplatin regimen ﻿

Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study ﻿

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study ﻿

Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): A randomized, noninferiority phase II trialwith a pharmacogenetic analysis ﻿

The BOMET-QOL questionnaire in patients with breast cancer and bone metastasis: The prospective MABOMET study from the Spanish breast cancer research group (GEICAM) ﻿

Third line chemotherapy in metastatic colorectal cancer: A single institution experience ﻿

Tolerability of raltitrexed when it is used in monotherapy and in combination with oxaliplatin (TOMOX) as advanced colorectal cancer treatment in normal clinical practice ﻿

Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts ﻿

BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

Control of SOCS1 and SOCS3 methylation, and relationship with MGMT as effectiveness factor of treatment in glioblastoma.

Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study

Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy

Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention

Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer

Pazopanib in metastatic renal carcinoma (mRC): Experience of 31 centers in Spain in first, second, third, or subsequent lines in daily clinical practice

Prevalence of cancer-related pain in different tumor entities, atlas study in Spanish oncology units

Prevalence of cancer-related pain in different tumor entities: ATLAS Study in Spanish oncology units

Prospective study into the necessity of hemogram on day 8 in oral vinorelbine and cisplatin regimen

Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): A randomized, noninferiority phase II trialwith a pharmacogenetic analysis

The BOMET-QOL questionnaire in patients with breast cancer and bone metastasis: The prospective MABOMET study from the Spanish breast cancer research group (GEICAM)

Third line chemotherapy in metastatic colorectal cancer: A single institution experience

Tolerability of raltitrexed when it is used in monotherapy and in combination with oxaliplatin (TOMOX) as advanced colorectal cancer treatment in normal clinical practice

Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts